Neurochem Get Positive Recommendation to Continue Trial for Alzhemed

Neurochem's independent safety review board (ISRB) has issued a recommendation to continue the company's North American Phase III clinical trial for Alzhemed for the treatment of Alzheimer's disease (AD).

Neurochem's ISRB for Alzhemed is made up of independent medical experts who monitor and evaluate the safety of patients taking part in the Alzhemed Phase III clinical trial in North America.

The recommendation by the ISRB members was based on their recent review of the safety data from 562 patients who have been monitored in the trial for at least 12 weeks so far. After reviewing the safety information, the ISRB concluded that there were no significant safety concerns to report in the study and that the trial should continue as planned.